ACC 2010 schedule: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(30 intermediate revisions by 2 users not shown)
Line 26: Line 26:
=== <font color="green">9:30 AM</font>===
=== <font color="green">9:30 AM</font>===


===10:00 AM===
===10:15 AM===
*'''Interviewee:'''  
*'''Interviewee:''' Robert M. Califf
*'''Trial:'''  
*'''Trial:''' The Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
 
===10:30 AM===
*'''Interviewee:'''
*'''Trial:'''


===11:00 AM===
===11:00 AM===
*'''Interviewee:''' Manesh R. Patel


===11:30 AM===
===<font color="green">11:30 AM</font>===


=== <font color="green">12:00 PM</font>===
=== <font color="green">12:00 PM</font>===
Line 64: Line 61:
==Sunday March 14, 2010==
==Sunday March 14, 2010==


===8:30 AM===
=== <font color="green">8:30 AM</font>===


===9:00 AM===
=== <font color="green">9:00 AM</font>===


===9:30 AM===
=== <font color="green">9:30 AM</font>===


=== <font color="green">10:00 AM</font>===
=== <font color="green">10:00 AM</font>===
Line 75: Line 72:


=== <font color="green">11:00 AM</font>===
=== <font color="green">11:00 AM</font>===
*'''Presenter:''' Mark Chan
*'''Presentation:''' Temporal Trends Over 15 Years in Clinical Trials of Non-ST Elevation Acute Coronary Syndromes: More Aggressive Treatment Yields Similar Mortality Despite Higher-Risk Profiles


===11:30 AM===
=== <font color="green">11:30 AM</font>===
*'''Presenter:''' Freek.W.A. Verheugt


===12:00 PM===
=== <font color="green">12:00 PM</font>===


===12:30 PM===
=== <font color="green">12:30 PM</font>===
*'''Interviewee:''' Tracy Y. Wang
*'''Presentation:''' Upfront Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Use in Patients with Acute Coronary Syndrome: An Analysis from the Early versus Delayed Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial


===1:00 PM===
=== <font color="green">1:00 PM</font>===
*'''Interviewee:''' Chiara Melloni
*'''Presentation:''' Safety and Efficacy of Adjusted-Dose Eptifibatide in Patients with Acute Coronary Syndromes and Reduced Renal Function


===1:30 PM===
===1:30 PM===
Line 101: Line 105:


===3:30 PM===
===3:30 PM===
*'''Interviewee:''' Gary Michael Felker
*'''Trial:''' The Diuretic Optimization Strategies Evaluation (DOSE) Study: A Randomized, Double Blind, Placebo-controlled Trial Of Diuretic Strategies In Acute Decompensated Heart Failure


===4:00 PM===
===4:00 PM===
Line 106: Line 112:
*'''Trial:''' The Impact of Remote Monitoring with Automatic Clinician Notifications on the clinical care of ICD and CRT-D Patients
*'''Trial:''' The Impact of Remote Monitoring with Automatic Clinician Notifications on the clinical care of ICD and CRT-D Patients


===4:30 PM===
=== <font color="green">4:30 PM</font>===


===5:00 PM===
===5:00 PM===
Line 123: Line 129:


===8:30 AM===
===8:30 AM===
*'''Interviewee:''' Peter Clemmensen
*'''Trial:''' Long-term Outcome after Drug-Eluting versus Bare-Metal Stent Implantation in Patients with ST-Elevation Myocardial Infarction. Three-year follow-up of the DEDICATION Trial


===9:00 AM===
===9:00 AM===
Line 149: Line 157:


=== <font color="green">1:00 PM</font>===
=== <font color="green">1:00 PM</font>===
*'''Interviewer:''': Bimal Shah


=== <font color="green">1:30 PM</font>===
=== <font color="green">1:30 PM</font>===


===2:15 PM===
===2:15 PM===
*'''Interviewee:''' Isabelle C. Van Gelder
*'''Interviewee:''' William C. Cushman
*'''Trial:''' Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison Between Lenient Versus Strict Rate Control in Patients With and Without Heart Failure. The RACE II Study
*'''Trial:''' Effects of Intensive Blood Pressure Control on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial


===2:30 PM===
===2:30 PM===
*'''Interviewee:''' Robert S. Epstein
*'''Trial:''' Effect of Genotyping Warfarin Patients on Outcomes: Results from the National Community-based Medco-Mayo Warfarin Effectiveness Study (MM-WES)


=== <font color="green">3:00 PM</font>===
===<font color="green">3:00 PM</font>===


=== <font color="green">3:30 PM</font>===
===<font color="green">3:30 PM</font>===
*'''Interviewee:''' Hisao Ogawa 


=== <font color="green">4:00 PM</font>===
===4:00 PM===
*'''Interviewee:''' Hisao Ogawa 
*'''Presentation:''' Endo-PAT evaluation of Endothelia function


=== <font color="green">4:30 PM</font>===
===4:30 PM===




Line 174: Line 188:


=== <font color="green">9:00 AM</font>===
=== <font color="green">9:00 AM</font>===
*'''Interviewer:''' Bimal R. Shah


===9:30 AM===
===9:30 AM===
Line 180: Line 195:


===10:00 AM===
===10:00 AM===
*'''Interviewee:''' Robert M. Califf
*'''Interviewee:'''  
*'''Trial:''' The Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
*'''Trial:'''  
 
===10:30 AM===
 
===11:00 AM===
 
 


''[[ACC 2010 schedule#Click on Date for Detailed Schedule|Return to top]]''
''[[ACC 2010 schedule#Click on Date for Detailed Schedule|Return to top]]''

Latest revision as of 20:31, 14 March 2010

Here is the page we will use to coordinate interviews at ACC 2010

Filming location: Atlanta Marriott Downtown 160 Spring Street Atlanta, GA 30303

Filming will occur from Saturday to Tuesday (March 13 - March 16). Dr. Gibson is available to interview during all times listed in black. For all times listed in green, Dr. Gibson is unavailable to conduct the interview. You may, however, go ahead and speak about your topic/present your slides.


Click on Date for Detailed Schedule

Saturday March 13, 2010

Sunday March 14, 2010

Monday March 15, 2010

Tuesday March 16, 2010

Saturday, March 13, 2010

9:00 AM

9:30 AM

10:15 AM

  • Interviewee: Robert M. Califf
  • Trial: The Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial

11:00 AM

  • Interviewee: Manesh R. Patel

11:30 AM

12:00 PM

12:30 PM

1:00 PM

1:30 PM

2:00 PM

2:30 PM

3:00 PM

3:30 PM

4:00 PM

4:30 PM

  • Interviewee: Hyo-Soo Kim
  • Trial: Randomized Trial Evaluating the Efficacy of Cilostazol on Ischemic Vascular Complications after Drug-eluting Stent Implantation for Coronary Heart Disease: Influence of Cilostazol-based triple anti-platelet therapy on Ischemic Complication after drug-eluting stent implantation (CILON-T) study

Return to top

Sunday March 14, 2010

8:30 AM

9:00 AM

9:30 AM

10:00 AM

10:30 AM

11:00 AM

  • Presenter: Mark Chan
  • Presentation: Temporal Trends Over 15 Years in Clinical Trials of Non-ST Elevation Acute Coronary Syndromes: More Aggressive Treatment Yields Similar Mortality Despite Higher-Risk Profiles

11:30 AM

  • Presenter: Freek.W.A. Verheugt

12:00 PM

12:30 PM

  • Interviewee: Tracy Y. Wang
  • Presentation: Upfront Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Use in Patients with Acute Coronary Syndrome: An Analysis from the Early versus Delayed Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial

1:00 PM

  • Interviewee: Chiara Melloni
  • Presentation: Safety and Efficacy of Adjusted-Dose Eptifibatide in Patients with Acute Coronary Syndromes and Reduced Renal Function

1:30 PM

  • Interviewee:
  • Trial:

2:00 PM

  • Interviewee: Francois Schiele
  • Trial: Effects of Clinical Characteristics and Treatments on Gender Difference in Outcomes after Acute Myocardial Infarction: A Propensity Score-Matched Analysis

2:30 PM

  • Interviewee: Michael Maeng
  • Trial: Randomized All-comer Comparison of Zotarolimus-eluting and Sirolimus-eluting Coronary Stents: 18-month Follow-up in the SORT OUT III Trial

3:00 PM

  • Interviewee: Michael D. Ezekowitz
  • Trial: A Randomized Clinical Trial of Three Doses of a Long-Acting Oral Direct Factor Xa Inhibitor Betrixaban in Patients With Atrial Fibrillation

3:30 PM

  • Interviewee: Gary Michael Felker
  • Trial: The Diuretic Optimization Strategies Evaluation (DOSE) Study: A Randomized, Double Blind, Placebo-controlled Trial Of Diuretic Strategies In Acute Decompensated Heart Failure

4:00 PM

  • Interviewee: George H. Crossley, III
  • Trial: The Impact of Remote Monitoring with Automatic Clinician Notifications on the clinical care of ICD and CRT-D Patients

4:30 PM

5:00 PM

  • Interviewee: Henry Ginsberg
  • Trial: Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The ACCORD Lipid Study


Return to top

Monday March 15, 2010

8:00 AM

  • Interviewee: Rhonda M. Cooper-Dehoff
  • Trial: Rethinking Lower BP Goals for Diabetics with Documented Coronary Artery Disease: Findings from the INternational VErapamil SR - Trandolapril STudy (INVEST)

8:30 AM

  • Interviewee: Peter Clemmensen
  • Trial: Long-term Outcome after Drug-Eluting versus Bare-Metal Stent Implantation in Patients with ST-Elevation Myocardial Infarction. Three-year follow-up of the DEDICATION Trial

9:00 AM

  • Interviewee: Robert A. Byrne
  • Trial: Randomized Trial of a Polymer-Free Dual Drug-Eluting Stent versus Polymer-Based Cypher and Endeavor Drug-Eluting Stents - Two-year Clinical and Angiographic Outcomes

9:30 AM

  • Interviewee: Steven Goldman
  • Trial: A Randomized Trial Radial Artery Grafts versus Saphenous Vein Grafts in Coronary Artery Bypass Surgery: VA Cooperative Study

10:00 AM

  • Interviewee: Ted Feldman
  • Trial: Primary Safety and Efficacy Endpoints of the EVEREST II Randomized Clinical Trial

10:20 AM

  • Interviewee: Claes Held
  • Trial: Ticagrelor Versus Clopidogrel In Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery: Results From The PLATO Trial

11:00 AM

11:30 AM

12:00 PM

12:30 PM

1:00 PM

  • Interviewer:: Bimal Shah

1:30 PM

2:15 PM

  • Interviewee: William C. Cushman
  • Trial: Effects of Intensive Blood Pressure Control on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial

2:30 PM

  • Interviewee: Robert S. Epstein
  • Trial: Effect of Genotyping Warfarin Patients on Outcomes: Results from the National Community-based Medco-Mayo Warfarin Effectiveness Study (MM-WES)

3:00 PM

3:30 PM

  • Interviewee: Hisao Ogawa

4:00 PM

  • Interviewee: Hisao Ogawa
  • Presentation: Endo-PAT evaluation of Endothelia function

4:30 PM

Return to top

Tuesday March 16, 2010

8:30 AM

9:00 AM

  • Interviewer: Bimal R. Shah

9:30 AM

  • Interviewee: David Antoniucci
  • Trial: Randomized Comparison of Angiojet Rheolytic Thrombectomy Before Direct Infarct Artery Stenting to Direct Stenting Alone in Patients with Acute Myocardial Infarction: the Jetstent Trial

10:00 AM

  • Interviewee:
  • Trial:

Return to top

Retrieved from "https://www.wikidoc.org/index.php?title=ACC_2010_schedule&oldid=565744"